coronavirus
Ensuring global access to COVID-19 vaccines
Mar
WHO warns of multiple simultaneous outbreaks of COVID-19 worldwide.
The development of COVID-19 vaccines that can be used globally is therefore a priority for ending the pandemic.
This consultation led to the launch of a COVID-19 Vaccine Development Taskforce that is now working on how to finance and manufacture vaccines for global access.
This estimate includes phase 1 clinical trials of eight vaccine candidates, progression of up to six candidates through phase 2 and 3 trials, completion of regulatory and quality requirements for at least three vaccines, and enhancing global manufacturing capacity for three vaccines. This estimate does not include the costs of manufacture or delivery. Progress has been rapid. A phase 1 trial of a vaccine candidate, supported by the US National Institutes of Health and CEPI, began on March 16, 2020,
and 2 days later a clinical trial began in China.
Clinical trials for other candidates will start soon.
Through this fund, CEPI can act as a global mechanism for funding vaccine development until vaccines can be licensed or used under emergency use provisions. Mobilising $2 billion in funding will require funding from all sources. Given the enormous health, social, and economic consequences of COVID-19, there is a strong case for all governments to invest in vaccines.
In addition to direct government contributions, innovative finance mechanisms have been successful in raising funds for vaccines in the past and should be used to fund the development of COVID-19 vaccines.
The International Finance Facility for Immunisation (IFFIm) raises funds with vaccine bonds, which turn long-term contributions by donors into available cash.
IFFIm was created to support Gavi, the Vaccine Alliance, but could be used to finance CEPI’s COVID-19 vaccine efforts. With advanced market commitments, donors make funding commitments to vaccine manufacturers and, in exchange, companies sign a legally binding commitment to provide the vaccines at a price affordable to low-income and middle-income countries. Gavi’s board expressed support for the use of Gavi’s IFFIm and advanced market commitments to improve COVID-19 vaccine development and access
The need for COVID-19 vaccines is global, although the need is differentially distributed within populations. Vaccines would likely be prioritised for health-care workers and people at greatest risk of severe illness and death. High-income countries must not monopolise the global supply of COVID-19 vaccines. This risk is real: during the 2009 influenza A/H1N1 pandemic, rich countries negotiated large advance orders for the vaccine, crowding out poor countries.
Such an outcome would result in a suboptimal allocation of an initially scarce resource.
High-level dialogue is needed on ways to ensure complementarity of efforts and global access to COVID-19 vaccines. Investments should proceed in tandem to build national systems for delivery of potential vaccines—eg, using domestic financing and external financing from the World Bank Group’s $14 billion COVID-19 Fast Track Facility
and reallocations from the Global Fund to Fight AIDS, Tuberculosis and Malaria, Gavi, and Global Financing Facility grants for service delivery.
